Meeting
2023 ASCO Annual Meeting
Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.
Authors
Keagan Lipak
Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute, NIH, Bethesda, MD
Keagan Lipak , Bonnie Yates , Nicole Binder , Haneen Shalabi , Cody J. Peer , William Douglas Figg , Edward Michael Gertz , Nirali N. Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT03448393
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10033)
DOI
10.1200/JCO.2023.41.16_suppl.10033
Abstract #
10033
Poster Bd #
339
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.
First Author: Jordan Gauthier
Poster
2023 ASCO Annual Meeting
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).
First Author: Frederick L. Locke
Poster
2023 ASCO Annual Meeting
Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
First Author: Emily C. Liang
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang